摘要
血管内皮生长因子受体是一种可诱导血管生成的受体型酪氨酸激酶,临床研究发现该激酶在肿瘤组织中过度表达。以抑制血管内皮生长因子受体为基础的抗血管生成疗法已成为癌症治疗的新策略,小分子血管内皮生长因子受体-2抑制剂的设计和合成获得了广泛关注。对近5年内血管内皮生长因子受体-2抑制剂的研究进展进行了综述。
Vascular endothelial growth factor receptor （VEGFR） is a kind of important tyrosine kinase, which can induce angiogenesis. It can be found ovcrexpressed in tumor tissues. Recently, the VEGFR-based anti-angiogenic therapy has become a new cancer treatment strategy. More and more small-molecule inhibitors of VEGFR-2 have been discovered. The design and synthesis of VEGFR-2 inhibitors have also drawn a wide public attention. The advances in research on VEGFR-2 inhibitors in the past 5 years have been reviewed in this paper.
出处
《药学进展》
CAS
2014年第1期14-24,共11页
Progress in Pharmaceutical Sciences
基金
国家自然科学基金资助项目(No.21302225)
